A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults

Conditions:   Safety;   Tolerability;   ReactogenicityIntervention:   Biological: PA83-FhCMBSponsor:   Fraunhofer, Center for Molecular BiotechnologyRecruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials